MEDI:GATE NEWS Daewoong Pharmaceutical’s patent lawsuit against generic sales…imposed a fine of 2.297 billion won
FTC’s accusation against Daewoong Pharm for’Gapjil of the replica drug’ and a penalty of KRW 2.3 billion… First sanction for abuse of patent rights
Medytox acquires shares of Daewoong Pharmaceutical’s U.S. partner Evolu, becoming the second largest shareholder
‘Botox War’ Medytox and Daewoong agreed to dispute with the US… Notice of bleeding again for domestic flights
Daewoong Pharmaceutical completely eliminates US business risks… Nabota global market penetration spur
Daewoong Pharmaceutical “Completely solved the business risk of’Nabota’ in the US.. Domestic lawsuit is in progress”
